Nail bed disorder
(UMLS:C2938897)
- UMLS ID:
- C2938897
- MeSH ID:
- N/A
Synonym(s)
1.
Nail bed disorder
Associated Drug(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Sunitinib | FAERS: 4 | US FAERS | |
| 2 | Lapatinib | FAERS: 3 | US FAERS | |
| 3 | Teriparatide | FAERS: 3 | US FAERS | |
| 4 | niraparib | FAERS: 3 | US FAERS | |
| 5 | Capecitabine | FAERS: 2 | US FAERS | |
| 6 | Erlotinib Hydrochloride | FAERS: 2 | US FAERS | |
| 7 | Ramipril | FAERS: 2 | US FAERS | |
| 8 | apremilast | FAERS: 2 | US FAERS | |
| 9 | palbociclib | FAERS: 2 | US FAERS | |
| 10 | teriflunomide | FAERS: 2 | US FAERS | |
| 11 | tofacitinib | FAERS: 2 | US FAERS | |
| 12 | Anastrozole | FAERS: 1 | US FAERS | |
| 13 | Ciprofloxacin | FAERS: 1 | US FAERS | |
| 14 | Cyclosporine | FAERS: 1 | US FAERS | |
| 15 | Dimethyl Fumarate | FAERS: 1 | US FAERS | |
| 16 | Doxycycline | FAERS: 1 | US FAERS | |
| 17 | Duloxetine Hydrochloride | FAERS: 1 | US FAERS | |
| 18 | Everolimus | FAERS: 1 | US FAERS | |
| 19 | Fingolimod Hydrochloride | FAERS: 1 | US FAERS | |
| 20 | Imatinib Mesylate | FAERS: 1 | US FAERS | |
| 21 | Lenalidomide | FAERS: 1 | US FAERS | |
| 22 | MDV 3100 | FAERS: 1 | US FAERS | |
| 23 | Methotrexate | FAERS: 1 | US FAERS | |
| 24 | Paclitaxel | FAERS: 1 | US FAERS | |
| 25 | Roflumilast | FAERS: 1 | US FAERS | |
| 26 | Tacrolimus | FAERS: 1 | US FAERS | |
| 27 | Tetrabenazine | FAERS: 1 | US FAERS | |
| 28 | Varenicline | FAERS: 1 | US FAERS | |
| 29 | efinaconazole | FAERS: 1 | US FAERS | |
| 30 | exemestane | FAERS: 1 | US FAERS | |
| 31 | obeticholic acid | FAERS: 1 | US FAERS | |
| 32 | osimertinib | FAERS: 1 | US FAERS | |
| 33 | rotigotine | FAERS: 1 | US FAERS | |
| 34 | tavaborole | FAERS: 1 | US FAERS |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120295
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.